Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Designer Disease-Fighting Proteins Being Developed

By R&D Editors | June 23, 2009

Researchers in the Department of Cardiovascular Sciences at the University of Leicester are developing a new way to make protein based drugs with potential applications in stroke, vascular inflammation, blood vessel formation, regenerative medicine and tissue engineering.

The research carried out by Shikha Sharma in Dr Nick Brindle’s group in Department of Cardiovascular Sciences aims to allow researchers to rapidly make ‘designer proteins’ that can bind to disease causing molecules in the body.

Shikha Sharma said “There are millions of different proteins that are involved in carrying out numerous functions in the human body. Over time each protein has evolved to optimise its function. Disease could result if any of these fail to perform efficiently.”

“By generating designer proteins in test tubes, we can produce molecules that have specific actions to control processes in the body. These proteins can be used to make drugs as a treatment for heart disease and cancer.”

She said: “Whilst most drugs in current use are synthetic, these designer molecules are developed from natural proteins and are likely to have fewer side effects. Proteins perform a well defined but complex set of function in the body and protein therapeutic drugs can perform better when compared to some synthetic small molecule drugs that may have unwanted interactions within the body.”

“Current methods to generate protein therapeutic are cumbersome and time consuming. At the University of Leicester, we have developed a novel method to revolutionise the way in which we produce these designer protein drugs. In principle this method mimics natural evolution to make new proteins but over a shorter timescale. Instead of taking millions of years, we can create new proteins in just a few weeks.”

She said: “The fact that this new method utilizes a similar mechanism by which antibodies are generated, suggests the output from this method will be as robust and dynamic as the wide range of antibodies produced in our bodies to fight the rapidly evolving viruses in the environment.”

Dr Brindle said: “Shikha has made great progress towards this new method, which holds the promise of new better drugs for a wide range of human and animal disease.”

In addition to medicine, the method holds promise for a wide range of applications in the chemical, pharmaceutical, and agricultural industries, such as generating protein molecules to prevent uptake of toxins in crops or protein molecules for detection of environmental pollutants.

Shikha Sharma will be presenting her research at the Festival of Postgraduate Research which is taking place on Thursday 25th June in the Belvoir Suite, Charles Wilson Building, University of Leicester between 11.30am and 1pm. This event is open to the public and is FREE to attend.

Date: June 11, 2009
Source: University of Leicester 

Related Articles Read More >

For the first time, scientists grow beating human-pig hearts for 21 days
Open-source Boltz-2 can speed binding-affinity predictions 1,000-fold
Thermo Fisher’s new Orbitrap Excedion Pro targets complex biotherapeutics for drug development
FDA’s new ‘Elsa’ AI set to expedite clinical protocol reviews
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE